An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Zymeworks Announces Participation in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Zymeworks Inc. (NYSE: ZYME) announced participation in two upcoming investor conferences in March 2022. The company will present at the Barclays Global Healthcare Conference on March 16 at 8:00 a.m. ET in Miami, FL, and a virtual fireside chat at Citi’s 2022 Winter Biotech Virtual Bus Tour on March 23 at 2:45 p.m. ET. Both events will be available via live webcast on Zymeworks’ website. Zymeworks is focused on developing next-generation biotherapeutics, including its lead candidate, zanidatamab, for treating solid tumors expressing HER2.
Positive
None.
Negative
None.
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences during March:
Barclays Global Healthcare Conference. Zymeworks will participate in one-on-one meetings and will present on March 16th at 8:00 a.m. ET in Miami, FL.
Citi’s 2022 Winter Biotech Virtual Bus Tour. Zymeworks will participate virtually in a fireside chat on March 23rd at 2:45 p.m. ET.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.
